BofA is adding Jazz Pharmaceuticals (JAZZ) to the firm’s “US 1 list,” which is intended to represent a collection of the best investment ideas that are drawn from the universe of Buy-rated, U.S.-listed stocks covered by BofA Global Research fundamental equity research analysts. The firm is removing R1 RCM (RCM) from the list.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAZZ:
- Jazz Pharmaceuticals price target lowered to $180 from $210 at Cantor Fitzgerald
- Jazz Pharmaceuticals price target raised to $217 from $204 at BofA
- Jazz Pharmaceuticals sees FY23 adjusted EPS $18.15-$19.00, consensus $17.48
- Jazz Pharmaceuticals resumed share repurchases in Q2
- Jazz Pharmaceuticals reports Q2 adjusted EPS $4.51, consensus $4.42